DBDmitrii V. Balashov

Dmitrii V. Balashov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitrii V. Balashov has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cardiovascular risk in a comorbid patient. A comparative analysis considering traditional risk factors

    by K.S. Solodenkova, M.A. Osadchuk, D.V. Balashov

    The issue of comorbidity in recent decades has become one of the most urgent in medicine and healthcare due to objective demographic processes and the high prevalence of cardiovascular, metabolic, and immune-mediated disorders. Cardiovascular events determine the prognosis in most comorbid patients, indicating the importance of correct assessment of cardiovascular risk (CVR). Objective. To perform a comparative analysis of the rate of traditional cardiovascular risk factors in patients with cardiovascular disorders (chronic ischemic heart disease (CIHD), hypertension, metabolic disorders (type 2 diabetes mellitus (DM), metabolic syndrome (MS), and obesity) and immuno-inflammatory conditions (rheumatoid arthritis — RA), depending on the presence of comorbidity and its type. Material and methods. The study included 160 patients with a verified CIHD, 132 patients with type 2 DM, 124 patients with verified RA, 94 patients with obesity (O) and/or MS, 60 patients with hypertension, and 40 apparently healthy individuals (HI). In each main group, subgroups were formed depending on the presence or absence of comorbidities. In the formed subgroups, demographic, anthropometric, and the most significant traditional CVR factors were compared; the correlation of risk factors (RF) and the Charlson comorbidity index (CI) was analyzed. Results. In the cohorts of comorbid patients, a high rate of traditional CVR factors was noted: the average number of RF ranged from 7.21 (CIHD +T2DM) to 3.86 (RA+O/MS) and statistically significantly exceeded the values in hypertension and HI groups. The cumulative CVR assessment using SCORE for individuals without CIHD and type 2 DM showed high risk in the RA+O/MS subgroup: the average score was 7.12±2.25%, with statistical significance versus hypertension and HI groups. When comparing the mean number of RFs in the comorbid and non-comorbid groups, statistically significant differences were found in the combination of CIHD and type 2 diabetes and the combination of CIHD and obesity or MS. Strong statistically significant correlation was established between Charlson CI and age, HDL-C decrease, the total number of traditional FR and the CVR degree. A moderate correlation was found between CI and BMI, total cholesterol, low-density lipoprotein cholesterol, and triglyceride levels. Conclusion. The combination of cardiovascular and metabolic or immuno-inflammatory disorders was characterized by more pronounced lipid profile disorders, a greater range of traditional risk factors, and a higher total cardiovascular risk. The comorbidity index correlated with individual risk factors, their number and degree of cardiovascular risk.

  • The influence of rosuvastatin on the efficacy of standard triple eradication therapy in patients with gallstone disease and Helicobacter pylori infection

    by E.D. Mironova, M.A. Osadchuk, D.V. Balashov

    ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить влияние розувастатина (гиполипидемического препарата) на эффективность литолитической и эрадикационной терапии у пациентов с желчнокаменной болезнью (ЖКБ). МАТЕРИАЛ И МЕТОДЫ В исследовании участвовали 122 пациента с конкрементами диаметром Helicobacter pylori. При обнаружении H. pylori назначалась тройная эрадикационная терапия в течение 14 дней с оценкой результатов через 4 недели. Всем испытуемым до лечения, спустя 3, 6, 9 и 12 мес проводили ультразвуковое исследование брюшной полости. До лечения, через 6 и 12 мес определяли показатели липидограммы в сыворотке крови. РЕЗУЛЬТАТЫ Наибольшая инфицированность H. pylori зафиксирована у пациентов с ГХ 1-й и 2-й групп: 66,6 и 67,5% соответственно. Наибольший уровень элиминации H. pylori достигнут у пациентов 2-й группы — 96,2%, наименьший у пациентов 1-й группы — 78,5% (pH. pylori целесообразно назначать розувастатин в качестве одного из компонентов литолитической и/или эрадикационной терапии.


  • Open Access

    Functional dyspepsia: a multifaceted problem in gastroenterology

    by Mikhail A. Osadchuk, Andrei A. Svistunov, Dmitrii V. Balashov

    The article presents the views on dyspepsia in world practice, data on the difficulties of diagnosis and the problem of the effectiveness of various therapy regimens. Particular attention is paid to the use of fixed forms of drugs for functional dyspepsia, in particular Omez DSR.